Abstract:There has been great progress in prognostic stratification since the advent of the eighth edition of the TNM staging system for lung cancer. Nevertheless, no consensus has been reached so far on the number of lymph nodes (LNs) evaluated during resection for stage I lung cancer. We thank Dr. Wo et al.1Dai J. Liu M. Yang Y. et al.Optimal lymph node examination and adjuvant chemotherapy for stage I lung cancer.J Thorac Oncol. 2019; 14: 1277-1285Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar for the positive feedback on our work and their comments on the differences in the evaluated LN number in previous population-based analyses. As reported by Dr. Wo and in our study, several optimal cutoff points in LN number have been proposed, ranging from 4 to 16, derived on the basis of various statistical models for prediction of stage migration and identification of survival benefit. The disparities in optimal LN examination among the studies could simply reflect the differences in inclusion criteria and model constructions, but more importantly, they could be owing to several inherent factors that were not captured by the published studies and databases, such as the Neighborhood Change Database and the Surveillance, Epidemiology, and End Results. First, most studies only incorporated tumor diameter and the main histopathologic type, whereas other tumor characteristics, for example, pathologic subtypes and the degree of differentiation, were not fully considered. In 2011, the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society jointly proposed a new adenocarcinoma classification, which not only indicates the invasive component of a tumor per se, but in addition implicates the strategic management of lung cancer. Adenocarcinomas that harbor micropapillary and solid pattern are reportedly more likely to have occult LN metastasis and benefit from adjuvant chemotherapy (AChT) even in their very early stages.2Tsao M.S. Marguet S. Le Teuff G. et al.Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection.J Clin Oncol. 2015; 33: 3439-3446Crossref PubMed Scopus (193) Google Scholar Therefore, surgeons tend to perform a thorough LN dissection for accurate staging if micropapillary and/or solid subtypes are indicated on intraoperative frozen sections and offer adjuvant interventions to potentially decrease recurrence. Second, a patient’s physical condition could also influence the extent of LN examination and administration of AChT. A recent review by our group revealed that patients with chronic obstructive pulmonary disease were at a higher risk of postoperative pulmonary complications and chemotherapy-related hazardous effects.3Dai J. Yang P. Cox A. Jiang G. Lung cancer and chronic obstructive pulmonary disease: from a clinical perspective.Oncotarget. 2017; 8: 18513-18524Crossref PubMed Scopus (43) Google Scholar Furthermore, a patient’s performance status (PS) plays a part in selecting an optimal therapeutic intervention, and an adequate lymphadenectomy is more often performed in patients with good PS, as AChT may benefit those with good PS more than those with poor PS.4Howington J.A. Blum M.G. Chang A.C. et al.Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.Chest. 2013; 143: e278S-e313SAbstract Full Text Full Text PDF PubMed Scopus (896) Google Scholar Apart from these identifiable elements (i.e., intrinsic biological behavior of a tumor and the patient’s functional status), some environmental factors have been usually underappreciated, such as the pathologist’s and surgeon’s behaviors. The thoroughness of pathology practice could affect the number of studied intrapulmonary LNs and discovery of N1 nodal metastasis. Moreover, surgeons with moderate experience tend to have higher yield of evaluated LNs than those with low and high experience.5Scheel 3rd, P.R. Crabtree T.D. Bell J.M. et al.Does surgeon experience affect outcomes in pathologic stage I lung cancer?.J Thorac Cardiovasc Surg. 2015; 149: 998-1004Abstract Full Text Full Text PDF PubMed Scopus (12) Google Scholar Overall, the exact LN number may be biased by various confounding factors, but it is encouraging that the number of LNs evaluated has been increasing during the past decade, indicating an adherence to lung cancer surgical quality standards, which ultimately will improve the outcomes of this devastating disease. This study has been funded by The National Natural Science Foundation of the People’s Republic of China (Grant No. 81802260) and the Shanghai Rising-Star Program (Grant No. 19QA1407400).

The role of extensive lymph node dissection in the new grading system for lung adenocarcinoma

110P the Role of Extensive Lymph Node Dissection in the New Grading System for Lung Adenocarcinoma

The IASLC Grading System for Invasive Pulmonary Adenocarcinoma: a Potential Prognosticator for Patients Receiving Neoadjuvant Therapy

Prognostic Impact of Lymphadenectomy on Outcomes of Sublobar Resection for Stage IA Non–small Cell Lung Cancer ≤2 Cm

The IASLC Proposed Grading System Accurately Predicts Prognosis and Mediastinal Nodal Metastasis in Patients With Clinical Stage I Lung Adenocarcinoma

Impact of Lymphadenectomy Extent on Immunotherapy Efficacy in Postresectional Recurred Non-Small Cell Lung Cancer: a Multi-Institutional Retrospective Cohort Study.

Significant difference in recurrence according to the proportion of high grade patterns in stage IA lung adenocarcinoma

The Extent of Mediastinal Lymph Node Dissection Correlates with Survival of Small Cell Lung Cancer Patients after Resection: a Propensity Score-Matched Cohort Study Analysis.

College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.

Effectiveness and Safety of Systematic and Selective Lymphadenectomies in Chinese Patients with Non-Small Cell Lung Cancer Who Received Sublobar Resection.

Proposed novel grading system for stage I invasive lung adenocarcinoma and a comparison with the 2020 IASLC grading system

Prognostic impact of pattern-based grading system by the new IASLC/ATS/ERS classification in Asian patients with stage I lung adenocarcinoma

[Prognostic Significance of a Newly Proposed Grading and Scoring System in Stage I Pulmonary Adenocarcinoma].

Validation Study of New IASLC Histology Grading System in Stage I Non-Mucinous Adenocarcinoma Comparing With Minimally Invasive Adenocarcinoma

A Novel Radiopathological Grading System to Tailor Recurrence Risk for Pathologic Stage IA Lung Adenocarcinoma.

Risk Factors of Recurrence for Resected T1aN0M0 Invasive Lung Adenocarcinoma: a Clinicopathologic Study of 177 Patients

IASLC grading system predicts distant metastases for resected lung adenocarcinoma

Identifiable and Unidentifiable Factors Influencing Lymph Node Examination and Adjuvant Chemotherapy in Stage I Lung Cancer

ASO Visual Abstract: Impact of Lymph Node Dissection on Survival and Tumor Recurrence in Patients with Resected Ct1-2N0 Small-Cell Lung Cancer

Prognostic impact of the newly revised IASLC proposed grading system for invasive lung adenocarcinoma: a systematic review and meta-analysis

Abstract 3782: IASLC grading system predict distant metastases for resected lung adenocarcinoma